Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment.
作者信息
Saloner Brendan, Stoller Kenneth B, Alexander G Caleb
机构信息
From the Departments of Health Policy and Management (B.S.) and Epidemiology (G.C.A.), Johns Hopkins Bloomberg School of Public Health, the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine (K.B.S.), the Center for Drug Safety and Effectiveness, Johns Hopkins University (G.C.A.), and the Division of General Internal Medicine, Department of Medicine, Johns Hopkins Medicine (G.C.A.) - all in Baltimore.
出版信息
N Engl J Med. 2018 Jul 5;379(1):4-6. doi: 10.1056/NEJMp1804059.
Abstract
摘要
相似文献
1
Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment.将成瘾治疗纳入主流——提高丁丙诺啡治疗质量
N Engl J Med. 2018 Jul 5;379(1):4-6. doi: 10.1056/NEJMp1804059.
2
Primary Care and the Opioid-Overdose Crisis - Buprenorphine Myths and Realities.初级保健与阿片类药物过量危机——丁丙诺啡的误区与真相
N Engl J Med. 2018 Jul 5;379(1):1-4. doi: 10.1056/NEJMp1802741.
3
Clinical treatment of opioid addiction and dependence.阿片类药物成瘾和依赖的临床治疗。
Methods Mol Med. 2003;84:285-95. doi: 10.1385/1-59259-379-8:285.
4
Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.美国食品药品监督管理局批准丁丙诺啡-纳洛酮用于门诊成瘾治疗。
Ann Intern Med. 2003 Feb 18;138(4):360. doi: 10.7326/0003-4819-138-4-200302180-00027.
5
Treatment options for opiate addiction.阿片类药物成瘾的治疗选择。
J Ky Med Assoc. 2004 May;102(5):221-4.
6
US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.2011 - 2016年期间，美国急诊科与阿片类药物相关的就诊人数增加，而用于阿片类药物使用障碍的药物使用情况难以察觉。
J Gen Intern Med. 2020 Mar;35(3):965-966. doi: 10.1007/s11606-019-05249-3.
7
Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.丁丙诺啡/纳曲酮在治疗多药成瘾及共病精神障碍方面的潜力。
Clin Pharmacol Ther. 2008 Apr;83(4):627-30. doi: 10.1038/sj.clpt.6100503. Epub 2008 Jan 23.
8
Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.年轻人经历非致命阿片类药物相关过量用药的特征和用药治疗情况。
Ann Emerg Med. 2020 Jan;75(1):29-38. doi: 10.1016/j.annemergmed.2019.07.030. Epub 2019 Oct 4.
9
Addiction treatment in Russia.俄罗斯的成瘾治疗。
Lancet. 2010 Oct 2;376(9747):1145. doi: 10.1016/S0140-6736(10)61537-1.
10
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.接受丁丙诺啡、美沙酮或纳曲酮维持治疗的阿片类物质使用障碍患者的围手术期注意事项
Anesthesiol Clin. 2018 Sep;36(3):345-359. doi: 10.1016/j.anclin.2018.04.002. Epub 2018 Jul 11.
引用本文的文献
1
Increasing medication assisted treatment in rural primary care practice: a qualitative comparative analysis from IT MATTTRs Colorado.在农村基层医疗实践中增加药物辅助治疗：来自科罗拉多州IT MATTTRs的定性比较分析。
Front Med (Lausanne). 2024 Oct 2;11:1450672. doi: 10.3389/fmed.2024.1450672. eCollection 2024.
2
Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018.阿片类物质使用障碍治疗中大量开处丁丙诺啡处方医生的重要性日益增加：2009-2018 年。
Drug Alcohol Depend. 2024 Jun 1;259:111290. doi: 10.1016/j.drugalcdep.2024.111290. Epub 2024 Apr 16.
3
What features of drug treatment programs help, or not, with access? a qualitative study of the perspectives of family members and community-based organization staff in Atlantic Canada.药物治疗项目的哪些特点有助于（或无助于）获得治疗？对加拿大大西洋地区家庭成员和社区组织工作人员观点的定性研究。
Subst Abuse Treat Prev Policy. 2024 Mar 22;19(1):20. doi: 10.1186/s13011-024-00602-0.
4
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology.患者报告结局测量及其在皮肤病学中的临床应用。
Am J Clin Dermatol. 2023 Jul;24(4):499-511. doi: 10.1007/s40257-023-00758-8. Epub 2023 Feb 1.
5
National trends in buprenorphine prescribing before and during the COVID-19 pandemic.新冠大流行前后丁丙诺啡处方的国家趋势。
J Subst Abuse Treat. 2023 Jan;144:108923. doi: 10.1016/j.jsat.2022.108923. Epub 2022 Oct 29.
6
Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder.专家组关于改善阿片类药物使用障碍治疗参与度和保持率的州级政策共识。
JAMA Health Forum. 2022 Sep 2;3(9):e223285. doi: 10.1001/jamahealthforum.2022.3285.
7
Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice.以患者为中心的阿片类药物使用障碍质量测量：为解决研究和实践中的差距而制定的分类法。
Subst Abus. 2022 Dec;43(1):1286-1299. doi: 10.1080/08897077.2022.2095082.
8
Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey.COVID-19 大流行期间阿片类药物治疗计划的安全措施：全州范围调查。
BMC Health Serv Res. 2022 Mar 30;22(1):418. doi: 10.1186/s12913-022-07832-7.
9
The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy.污名对阿片类药物使用障碍患者、阿片类药物治疗及政策的影响
Subst Abuse Rehabil. 2022 Jan 25;13:1-12. doi: 10.2147/SAR.S304566. eCollection 2022.
10
Studying how state health services delivery policies can mitigate the effects of disasters on drug addiction treatment and overdose: Protocol for a mixed-methods study.研究国家卫生服务提供政策如何减轻灾害对毒品成瘾治疗和过量用药的影响：混合方法研究方案。
PLoS One. 2021 Dec 16;16(12):e0261115. doi: 10.1371/journal.pone.0261115. eCollection 2021.
本文引用的文献
1
Association between process measures and mortality in individuals with opioid use disorders.阿片类物质使用障碍患者的过程指标与死亡率之间的关联。
Drug Alcohol Depend. 2017 Aug 1;177:307-314. doi: 10.1016/j.drugalcdep.2017.03.033. Epub 2017 Jun 27.
2
Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population.多州人群中丁丙诺啡-纳洛酮治疗阿片类物质使用障碍的模式
Med Care. 2017 Jul;55(7):669-676. doi: 10.1097/MLR.0000000000000727.
3
Association Between Hospitals' Engagement in Value-Based Reforms and Readmission Reduction in the Hospital Readmission Reduction Program.医院参与基于价值的改革与“降低医院再入院计划”中的再入院率降低之间的关联。
JAMA Intern Med. 2017 Jun 1;177(6):862-868. doi: 10.1001/jamainternmed.2017.0518.
4
Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.佛蒙特州阿片类药物使用障碍的中心辐射式护理模式：发展、实施与影响
J Addict Med. 2017 Jul/Aug;11(4):286-292. doi: 10.1097/ADM.0000000000000310.
Zotero 插件